US OptionsDetailed Quotes
CUE250117P2000
- 0.53
- 0.000.00%
15min DelayClose Jan 6 16:00 ET
0.00High0.00Low
0.53Open0.53Pre Close0 Volume5 Open Interest2.00Strike Price0.00Turnover309.35%IV16.00%PremiumJan 17, 2025Expiry Date0.25Intrinsic Value100Multiplier11DDays to Expiry0.28Extrinsic Value100Contract SizeAmericanOptions Type-0.4924Delta0.4271Gamma3.30Leverage Ratio-0.0174Theta-0.0004Rho-1.63Eff Leverage0.0012Vega
Cue Biopharma Stock Discussion
Sign in to post a comment
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
28
9
7
$Cue Biopharma (CUE.US)$
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
Cue Biopharma presented updated Phase 1 trial data for CUE-101 and CUE-102 at SITC 2024. CUE-101 combined with KEYTRUDA showed impressive results in head and neck cancer patients, achieving a 46% objective response rate and 91.3% 12-month overall survival. The median overall survival reached 21.8 m...
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
Cue Biopharma presented updated Phase 1 trial data for CUE-101 and CUE-102 at SITC 2024. CUE-101 combined with KEYTRUDA showed impressive results in head and neck cancer patients, achieving a 46% objective response rate and 91.3% 12-month overall survival. The median overall survival reached 21.8 m...
1
$Cue Biopharma (CUE.US)$ keep an eye on this one. They have a contract with Pfizer might have trial info coming out and that could be a reason for the movement 🍻
1
1
30 Stocks below $2 to watch out for high risk high return.
Pharmaceutical: $Esperion Therapeutics (ESPR.US)$ $Seelos Therapeutics (SEEL.US)$ $Scilex Holding (SCLX.US)$ $Trevena (TRVN.US)$ $111 Inc (YI.US)$ $Cue Biopharma (CUE.US)$
Frac Sand: $Smart Sand (SND.US)$
Graphite Electrode: $GrafTech (EAF.US)$
Crypto Mining: $Bit Origin (BTOG.US)$
Artificial Intelligence: $Veritone (VERI.US)$
IOT Security: $Gorilla Technology (GRRR.US)$
Holographic: $WiMi Hologram Cloud (WIMI.US)$
Real Est...
Pharmaceutical: $Esperion Therapeutics (ESPR.US)$ $Seelos Therapeutics (SEEL.US)$ $Scilex Holding (SCLX.US)$ $Trevena (TRVN.US)$ $111 Inc (YI.US)$ $Cue Biopharma (CUE.US)$
Frac Sand: $Smart Sand (SND.US)$
Graphite Electrode: $GrafTech (EAF.US)$
Crypto Mining: $Bit Origin (BTOG.US)$
Artificial Intelligence: $Veritone (VERI.US)$
IOT Security: $Gorilla Technology (GRRR.US)$
Holographic: $WiMi Hologram Cloud (WIMI.US)$
Real Est...
12
2
4
$uniQure NV (QURE.US)$ $Apogee Enterprises (APOG.US)$ $Capricor Therapeutics (CAPR.US)$ $noco-noco (NCNC.US)$ $UP Fintech (TIGR.US)$ $JBDI Holdings (JBDI.US)$ $Snail (SNAL.US)$ $Cue Biopharma (CUE.US)$ $Entero Therapeutics (ENTO.US)$ $Power REIT (PW.US)$ $Ford Motor (F.US)$ $Beneficient (BENF.US)$ $Phoenix Motor (PEV.US)$ $Chanson International (CHSN.US)$
📊⚡️📊
📊⚡️📊
3
3
1
No comment yet
AddiBee0925 : Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Jaguar8 OP AddiBee0925 : Yes. But there might be a build up of the price before the launch just like LUNR. Hopefully it goes well.
AddiBee0925 Jaguar8 OP : yeah I'm thinking the same
Jaguar8 OP browny_440 : TNXP will be good if FDA releases decision soon
72306783 : I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
View more comments...